Feedback from a European Bioanalysis Forum survey on bioanalysis of drugs in tissues

Author:

Mokrzycki Nathalie1,Delrat Pascal2,Meulder Marc De3,Erbach Eva4,Lenthéric Irene5,McIntosh Morna6,Dzygiel Pawel7,Timmerman Philip3

Affiliation:

1. Laboratoires Merck Sharp & Dohme-Chibret, Route de Marsat, Riom, 63963 Clermont-Ferrand Cedex 9, France

2. Technologie SERVIER, 25/27 rue Vignat, 45000 Orléans, France

3. Janssen Research & Development, a division of Janssen Pharmaceutica N.V. Turnhoutseweg 30, 2340 Beerse, Belgium

4. Bayer Pharma AG Global Drug Discovery, Global Early Development, Drug Metabolism & Pharmacokinetics Müllerstr. 178, Gebäude S109, Raum 220A 13353 Berlin, Germany

5. Harlan Laboratories S.A. Argenters, 6 08130 Santa Perpetua de Mogoda Barcelona, Spain

6. Charles River Laboratories, Bioanalysis & Immunology, Charles River Tranent, Edinburgh, EH33 1NE

7. Hoffman-La Roche AG, Grenzacherstrasse 124 CH-4070 Basel Switzerland

Abstract

Tissue analysis has always been a difficult discipline of bioanalysis. Laboratories that perform bioanalysis in tissue are facing a lot of challenges and questions before starting experiments, from a scientific/technical point of view regarding more regulated aspects. Actually, literature is poor regarding the more technical and scientific aspects but also beyond that no clear guidance is available on this topic and laboratories performing tissue analysis face real ambiguity regarding regulatory requirements, always with the risk of under- or over-validation of the assay. For all of these reasons bioanalysis in tissue became a frequently discussed topic within the European Bioanalytical Forum (EBF) organization. The EBF then decided to treat this as a specific topic, and carried out a survey that was done in two steps between 2012 and 2013. This paper represents an exhaustive summary of the result of this survey that includes themost important aspects of tissue bioanalysis. This survey provided the team a good starting point for their discussions and resulted in an EBF recommendation paper published separately.

Publisher

Future Science Ltd

Subject

Medical Laboratory Technology,Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,General Medicine,Analytical Chemistry

Reference10 articles.

1. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Guidance for Industry. Bioanalytical Method Validation. CDER, Rockville, MD, USA (2001). www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf 

2. Tissue bioanalysis of biotherapeutics and drug targets to support PK/PD

3. Tissue analysis – a powerful tool for drug discovery and development

4. Bioanalysis of drug in tissue: current status and challenges

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3